<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1959">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05135663</url>
  </required_header>
  <id_info>
    <org_study_id>NS089/NCNP02-P2OE</org_study_id>
    <secondary_id>jRCT2031210162</secondary_id>
    <nct_id>NCT05135663</nct_id>
  </id_info>
  <brief_title>Extension Study of NS-089/NCNP-02 in DMD</brief_title>
  <official_title>A Phase II, Open-Label, Extension Study of NS-089/NCNP-02 in Patients With Duchenne Muscular Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nippon Shinyaku Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nippon Shinyaku Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is the extension study of NS-089/NCNP-02 (Study NCNP/DMT02), which is designed to assess&#xD;
      the safety, tolerability and efficacy of NS-089/NCNP-02 in patients with Duchenne muscular&#xD;
      dystrophy (DMD).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 23, 2021</start_date>
  <completion_date type="Anticipated">July 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to Week 102</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Expression of dystrophin protein (Western blot)</measure>
    <time_frame>Week 99</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of exon 44-skipped mRNA of dystrophin</measure>
    <time_frame>Week 99</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>North Star Ambulatory Assessment (NSAA)</measure>
    <time_frame>Up to Week 99</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to stand test</measure>
    <time_frame>Up to Week 99</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to run/walk 10 meters test</measure>
    <time_frame>Up to Week 99</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Six-minute walk test/Two-minute walk test</measure>
    <time_frame>Up to Week 99</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Timed Up &amp; Go test</measure>
    <time_frame>Up to Week 99</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative muscle strength assessment</measure>
    <time_frame>Up to Week 99</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance of Upper Limb test</measure>
    <time_frame>Up to Week 99</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum creatine kinase concentration from baseline</measure>
    <time_frame>Up to Week 99</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Duchenne Muscular Dystrophy (DMD)</condition>
  <arm_group>
    <arm_group_label>NS-089/NCNP-02 40 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>NS-089/NCNP-02 80 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NS-089/NCNP-02</intervention_name>
    <description>The same dose administered in as Part 2 of Study NCNP/DMT02 (40 mg/kg) will be administered once weekly for 72 weeks.</description>
    <arm_group_label>NS-089/NCNP-02 40 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NS-089/NCNP-02</intervention_name>
    <description>The same dose administered in as Part 2 of Study NCNP/DMT02 (80 mg/kg) will be administered once weekly for 72 weeks.</description>
    <arm_group_label>NS-089/NCNP-02 80 mg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient completed Study NCNP/DMT02&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient had any serious adverse events in Study NCNP/DMT02 that, in the opinion of the&#xD;
             Investigator and/or Sponsor, was probably or definitely related to NS-089/NCNP-02 use&#xD;
             and precludes safe use of NS-089/NCNP-02 for the patient in this study.&#xD;
&#xD;
          2. Patient had a treatment which was made for the purpose of dystrophin or&#xD;
             dystrophin-related protein induction after completion of Study NCNP/DMT02.&#xD;
&#xD;
          3. Patient took any other investigational drugs after completion of Study NCNP/DMT02.&#xD;
&#xD;
          4. Patient was judged by the investigator and/or the Sponsor that it was not appropriate&#xD;
             to participate in the extension study for other reasons.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kagoshima University Hospital</name>
      <address>
        <city>Kagoshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Center of Neurology and Psychiatry</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 5, 2021</study_first_submitted>
  <study_first_submitted_qc>November 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

